Edward Yen

Assistant Pharmacy Director - Riverside University Health System

📍 United States🔄 Updated September 2026💼 1 investments📅 9 years investing🗓 Last invested Dec 2017
Angel investor🌍 United States
1
Total investments
1
Early stage
0
Mid stage
0
Late stage
9y
Years active

Portfolio

1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Angel Investor
Dec 2017
CB Therapeutics is an innovative producer of high value molecules, compounds and rare ingredients from simple feedstock utilizing many different types of hosts and systems, including yeast, bacteria and cell-free expression systems. CB Therapeutics’ expertise in synthetic genomics, bio-engineering and cellular production processes can produce a broad range of phytochemicals faster, more sustainably, at greater yields and with higher purity, consistency and efficiency than competitive platforms. CB Therapeutics is focused on the discovery, research, development and production of tryptamines, cannabinoids and other molecules and compounds to advance Neuroscience and bring therapeutics to market to solve mankind’s most challenging mental healthcare and social problems.
early stageBiotechnology
Experience · 1 entries
All (1)
Investments (1)
2017
Angel Investor
Dec 2017
CB Therapeutics is an innovative producer of high value molecules, compounds and rare ingredients from simple feedstock utilizing many different types of hosts and systems, including yeast, bacteria and cell-free expression systems. CB Therapeutics’ expertise in synthetic genomics, bio-engineering and cellular production processes can produce a broad range of phytochemicals faster, more sustainably, at greater yields and with higher purity, consistency and efficiency than competitive platforms. CB Therapeutics is focused on the discovery, research, development and production of tryptamines, cannabinoids and other molecules and compounds to advance Neuroscience and bring therapeutics to market to solve mankind’s most challenging mental healthcare and social problems.
early stageBiotechnology